Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATIVAN vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
98% bound to albumin and alpha-1-acid glycoprotein.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
0.8 L/kg; indicates moderate tissue distribution.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATIVAN vs AZMIRO, answered by our medical review team.
ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATIVAN and AZMIRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATIVAN and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.